{
    "N/R/U": null,
    "Applicant": "UCB, Inc.",
    "BLA Number": "761151",
    "Proprietary Name": "Bimzelx",
    "Proper Name": "bimekizumab-bkzx",
    "BLA Type": "351(a)",
    "Strength": "320MG/2ML (160MG/2ML)",
    "Dosage Form": "Injection ",
    "Route of Administration": "Subcutaneous",
    "Product Presentation": "Autoinjector",
    "Marketing Status": "Rx",
    "Licensure": "Licensed",
    "Approval Date": "October 11, 2024",
    "Ref. Product Proper Name": null,
    "Ref. Product Proprietary Name": null,
    "Supplement Number": "9",
    "Submission Type": "Supplement",
    "License Number": "1736",
    "Product Number": "004",
    "Center": "CDER",
    "Date of First Licensure": null,
    "Exclusivity Expiration Date": null,
    "First Interchangeable Exclusivity Exp. Date": null,
    "Ref. Product Exclusivity Exp. Date": null,
    "Orphan Exclusivity Exp. Date": null
}